TY  - CHAP
M1  - Book, Section
TI  - Colorectal Cancer
A1  - Holle, Lisa M.
A1  - Clement, Jessica M.
A1  - Davis, Lisa E.
A2  - DiPiro, Joseph T.
A2  - Talbert, Robert L.
A2  - Yee, Gary C.
A2  - Matzke, Gary R.
A2  - Wells, Barbara G.
A2  - Posey, L. Michael
PY  - 2017
T2  - Pharmacotherapy: A Pathophysiologic Approach, 10e
AB  - Patient  Care  Process  for  the  Management  of  Colorectal  CancerCollectPatient  characteristics  (e.g.,  age,  race,  sex)Patient  history  (lifestyle  factors  –  alcohol  use,  tobacco  use,  physical  activity)Patient  characteristics  (e.g.,  social  history/situation,  insurance  coverage)  and  treatment  preferencesPatient  medical  and  family  history  (e.g,  performance  status,  concurrent  disease  states  [inflammatory  bowel  disease,  colorectal  cancer,  polyps])Clinical  presentation  signs  and  symptoms  (see  Clinical  Presentation  Box)Current  signs  and  symptoms  and  evaluation  of  tumor  growth  (for  follow-up  visits)Current  medications  (prescription,  over-the-counter,  and  complementary  or  alternative)  Objective  dataBP,  heart  rate  (HR),  height,  weight,  and  BSALabs  (e.g.  serum  electrolytes,  renal  function,  liver  chemistries,  complete  blood  count,  coagulation  studies,  carcinoembryonic  antigen  [CEA]  level  –  see  Workup)Physical  examination  data  (e.g.,  hepatomegaly,  lymphadenopathy,  ascites)Colorectal  cancer  staging  (see  Table  130-6)Colorectal  tumor  genomics  (e.g.,  KRAS,  NRAS,  MSI,  BRAF,PIK3CA;  see  Table  130-11)AssessRisk  factors  for  treatment-related  toxicities  (e.g.,  UGT1A1*28  genotype,  poor  nutritional  intake,  uncontrolled  blood  pressure  or  hypertension,  baseline  peripheral  neuropathy)Type  of  and  response  to  prior  treatmentsPotential  for  disease  responsiveness  to  specific  agents  and  risk  factors  for  disease  recurrencePotential  problems  with  medication  adherence  to  oral  treatment  regimensNeed  for  drug  dose  reductions  or  supportive  carePlan*Goals  of  treatment  (initial  or  continued)Drug  therapy  regimen  including  specific  anticancer  agent(s),  dose,  route,  frequency,  and  duration  (see  Tables  130-7,  130-8,  130-10)Supportive  care  plan  (e.g.,  antiemetics,  prophylactic  antidiarrheals,  infusion  reaction  prophylaxis)Monitoring  parameters  including  efficacy  (e.g.,  cancer  imaging  studies-chest,  abdominal,  and/or  pelvic  CT  scans  and  radiographs,  CEA  if  previously  elevated,  symptoms  of  recurrence),  safety  (medication-specific  adverse  effects,  including  major-dose  limiting  toxicities),  and  timeframe  (see  Table  130-8)Patient  education  (e.g.,  goals  of  treatment,  expected  and  potential  serious  toxicities,  drug  therapy,  and  monitoring  and  management  plan)Implement*Provide  patient  education  regarding  all  elements  of  treatment  plan  Survivorship  care  plan  (e.g.,  primary  prevention  of  other  diseases,  such  as  infections,  and  other  cancers,  support  systems  for  maintaining  healthy  lifestyle  choices  and  BMI)Follow-up:  Monitor  and  EvaluateDetermine  disease  response  to  treatment  (see  Evaluation  of  Therapeutic  Outcomes)  and  occurrence  of  disease  progression  or  recurrence  (cancer  imaging  studies-chest,  abdominal,  and/or  pelvic  CT  scans  and  radiographs,  CEA  if  previously  elevated)Presence  of  adverse  effects  (see  Evaluation  of  Therapeutic  Outcomes  section  and  Table  130-8)Patient  adherence  to  treatment  plan  using  multiple  sources  of  information  (e.g.,  patient  self-report,  medication  administration  records  or  refill  data)Patient's  satisfaction  with  treatment,  including  understanding  of  adherence*Collaborate  with  patient,  caregivers,  and  other  health  professionals  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/19
UR  - accesspharmacy.mhmedical.com/content.aspx?aid=1148581484
ER  -